Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Culmerciclib + Letrozole + Trastuzumab + Pertuzumab in HR+/HER2+ Breast Cancer
NCT07795424Phase 2Not yet recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Sep 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
A Phase 2 trial of culmerciclib in breast cancer, sponsored by Shengjing Hospital of China Medical University. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
culmerciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07795424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07795424.